Pelthos Therapeutics (NYSEAMERICAN:PTHS) Releases Quarterly Earnings Results, Beats Estimates By $0.79 EPS

Pelthos Therapeutics (NYSEAMERICAN:PTHS) issued its quarterly earnings data on Thursday. The company reported ($2.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.83) by $0.79, FiscalAI reports. The business had revenue of $15.39 million during the quarter. Pelthos Therapeutics had a negative return on equity of 204.71% and a negative net margin of 165.24%.

Here are the key takeaways from Pelthos Therapeutics’ conference call:

• Zelsuvmi generated $15.2 million in Q3 net revenue, up 114% year over year, with prescriptions rising 365% year over year and more than 10,000 HCPs prescribing to date. The company also reported new coverage agreements expanding commercial formulary access to 127 million lives, though revenue edged down from $15.4 million in Q2.
• Zelsuvmi’s gross-to-net rate increased to 31.5% in Q3 from 29.6% in Q2, partly reflecting the new PBM contract; management expects it to reach the mid-30% range as coverage expands. Executives expect the access investment to support future growth, but its revenue benefit may take multiple quarters to emerge.
• Pelthos is building launch inventory for Xepi and expects to begin promotion by the end of Q1 2027; it expects to launch XEGLYZE by the end of Q3 2027. Management expects both products to leverage its existing commercial infrastructure, although Xepi will compete with inexpensive generic treatments.
• The planned Castle Creek Biosciences transaction would add D-Fi, an investigational cell therapy for dystrophic epidermolysis bullosa, with Pelthos expecting to continue Phase III development after closing, anticipated in Q1 2027. Management sees strategic and commercial potential, but D-Fi remains unapproved and its differentiation and clinical benefit have yet to be established in Phase III.
• Pelthos ended Q3 with $17.7 million in cash and reported a $7.9 million net loss; it borrowed an additional $10 million under its Horizon facility after quarter-end. Management said projected cash flows and funding provide flexibility to advance its plans, while another potential $10 million borrowing is conditional on lender discretion and specified requirements.

Pelthos Therapeutics Stock Down 13.6%

Shares of Pelthos Therapeutics stock traded down $1.28 during trading hours on Thursday, hitting $8.11. The company had a trading volume of 109,925 shares, compared to its average volume of 34,422. The company’s 50-day moving average is $18.84 and its two-hundred day moving average is $23.62. The company has a market cap of $31.06 million, a P/E ratio of -0.37 and a beta of 3.41. Pelthos Therapeutics has a twelve month low of $7.78 and a twelve month high of $36.75. The company has a debt-to-equity ratio of 3.40, a current ratio of 1.98 and a quick ratio of 1.31.

Analyst Upgrades and Downgrades

PTHS has been the subject of several research reports. Zacks Research raised Pelthos Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Wednesday, November 4th. Alliance Global Partners reissued a “buy” rating on shares of Pelthos Therapeutics in a research note on Monday, October 26th. Oppenheimer dropped their price objective on shares of Pelthos Therapeutics from $66.00 to $64.00 and set an “outperform” rating for the company in a report on Friday, August 14th. Finally, Lake Street Capital cut their target price on shares of Pelthos Therapeutics from $50.00 to $40.00 and set a “buy” rating on the stock in a research note on Monday, October 12th. Seven research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $52.83.

Institutional Inflows and Outflows

An institutional investor recently raised its stake in Pelthos Therapeutics stock. Knott David M Jr raised its holdings in Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) by 9.3% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 21,073 shares of the company’s stock after purchasing an additional 1,792 shares during the quarter. Knott David M Jr owned 0.63% of Pelthos Therapeutics worth $443,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 77.96% of the company’s stock.

About Pelthos Therapeutics

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).